Results 181 to 190 of about 6,340,743 (257)

Progression-free survival and objective response rate as a surrogate end point for overall survival in metastatic renal cell carcinoma: A systematic review and meta-analysis. [PDF]

Cancer
Leong R, Chen D, Almasri L, Lum N, Xiao K, Soleimani M, Kollmannsberger CK, Raman S.   +7 more
europepmc   +1 more source

Prevention of Early Onset of Breast Cancer With Ashwagandha

Molecular Carcinogenesis, EarlyView.
ABSTRACT Prevention of breast cancer is feasible because many risk factors for this malignancy are known (e.g., family history, reproductive factors, etc.). Medicinal plants and/or their bioactive phytochemicals are attractive for the prevention of early onset of breast cancer due to their generally favorable safety profile.
Eun‐Ryeong Hahm, Su‐Hyeong Kim, Shivendra V. Singh   +2 more
wiley   +1 more source

Characterization of aberrant alternative splicing landscape in patients with metastatic renal cell carcinoma. [PDF]

J Immunother Cancer
Govindarajan A, Hansen N, Mercier BD, Byron SA, Hegde A, Garcia-Mansfield K, Leskoske K, Chawla N, Meza L, Zengin Z, Barragan-Carillo R, Ebrahimi H, Castro DV, Dizman N, Hsu J, Chehrazi-Raffle A, Tripathi A, Salgia NJ, Pal SK, Pirrotte P.   +19 more
europepmc   +1 more source

Integration of scRNA‐Seq and scATAC‐Seq Revealed the Role of lncRNA RP11‐661C8.2 by Promoting EMT in Clear Cell Renal Cell Carcinoma

Molecular Carcinogenesis, EarlyView.
ABSTRACT Long noncoding RNAs (lncRNAs) play an important role in tumor progression. However, most of the previously discovered lncRNAs that promote or inhibit tumor progression were derived from bulk RNA‐seq results. Data from single‐cell RNA sequencing (scRNA‐seq) and single‐cell assay for transposase‐accessible chromatin using sequencing (scATAC‐seq)
Jizhen Cen, Xuefang Liang, Zheng Wen, Shengzhu Huang, Jiaping Li, Haibiao Yan, Kaiqiang Tang, Guifen Zhou, Ning Liang, Qi Zheng, Cheng Su, Zengnan Mo, Zhenyuan Yu   +12 more
wiley   +1 more source

Primary Resistance to Immune Checkpoint Inhibitor Combination Therapy in Metastatic Renal Cell Carcinoma: Focus on Nivolumab Plus Ipilimumab. [PDF]

Int J Urol
Numakura K, Abe N.
europepmc   +1 more source

Artificial Intelligence for Identifying Tumor‐Reactive CD8+ T Cells: Biological Principles, Computational Advances, and Future Directions

Med Research, EarlyView.
This review details a three‐stage paradigm shift for tumor‐reactive CD8+ T‐cell identification: decoding transcriptomic states, deciphering clonal functional efficacy, and molecular‐level therapeutic TCR design. Addressing translational hurdles and generative AI “scientific blind spots”—such as missing catch bonds—we present a visionary roadmap.
Chao Yang, Yingying Sun, Yan Zhang, Yifen Shi, Zhiwen Shi   +4 more
wiley   +1 more source

Association Between Body Mass Index and Treatment Toxicity in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib. [PDF]

Cancers (Basel)
Dişli AK, Nuransoy Cengiz A, Cengiz M, Buğday İ, Yıldırım S, Gönül R, Bozkurt O, İnanç M, Özkan M.   +8 more
europepmc   +1 more source

Organoid Coculture Models for Cancer Research and Immunotherapy

Med Research, EarlyView.
This review summarizes organoid coculture platforms, including submerged Matrigel culture, air–liquid interface, microfluidic/organoid‐on‐a‐chip, and 3D bioprinting, for reconstructing the tumor microenvironment to study tumor–stroma/immune crosstalk, evaluate immunotherapies, and enable drug screening.
Zhuo Yang, Huihui Yang, Guangxin Li, Guobang Liu, Zhulan Chen, Wenzhi Tian, Meiyang Huang, Xiaoling Liu, Yongsheng Zhao, Dong Chen   +9 more
wiley   +1 more source

4-weekly avelumab plus axitinib in patients with metastatic renal cell carcinoma. [PDF]

BJC Rep
Vasudev NS, Aleem U, Humphries K, Pillai M, Pickwell-Smith B, Ralph C, Jagdev S, Simpson J, Dearden H, Waddell T.   +9 more
europepmc   +1 more source

AI‐Driven Rational Design of Nanotherapeutics for Pancreatic Ductal Adenocarcinoma

Medicinal Research Reviews, EarlyView.
ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains a formidable malignancy characterized by late diagnosis, high recurrence rates, and pronounced chemoresistance. While nanoparticle‐based drug delivery systems (NDDS) offer theoretical advantages over conventional therapies, their clinical translation in PDAC has been severely limited.
Seohyun Choo, Kaeun Chae, Jueun Lee, Inseon Kim, Seunghun S. Lee   +4 more
wiley   +1 more source